Cue Biopharma
CUE
55 hedge funds and large institutions have $4.95M invested in Cue Biopharma in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
17% more funds holding
Funds holding: 47 → 55 (+8)
0.19% less ownership
Funds ownership: 0.92% → 0.73% (-0.19%)
26% less capital invested
Capital invested by funds: $6.66M → $4.95M (-$1.71M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$81.3K |
| 2 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$41.1K |
| 3 |
AP
Advisortrust Partners
Raleigh,
North Carolina
|
+$15.6K |
| 4 |
VF
Virtu Financial
New York
|
+$15.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$215K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.9K |
| 3 |
Jane Street
New York
|
-$21.3K |
| 4 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
-$13.5K |
| 5 |
LPL Financial
San Diego,
California
|
-$9.57K |
CUE Hedge Fund Activity: Q1 2026 in Review
55 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2026, worth a combined $4.95M — down 26% from $6.66M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CUE positions and 5 closed out — a net gain of 10 holders — while 4 added to existing stakes and 9 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $81.3K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $215K sold.
- 55 institutional investors held Cue Biopharma (CUE) as of Q1 2026, up from 47 in Q4 2025.
- Funds reported $4.95M of Cue Biopharma stock for Q1 2026, down 26% quarter-over-quarter.
- 15 funds opened new Cue Biopharma positions in Q1 2026 and 5 closed out, a net change of +10 holders.
- The largest Cue Biopharma buyer in Q1 2026 was Geode Capital Management, an estimated $81.3K added.
- The largest Cue Biopharma seller in Q1 2026 was Boothbay Fund Management, an estimated $215K sold.
Based on aggregated 13F filings for Q1 2026.